Each point was worked out with the data available that day. Scale 0-10: 5 is the index average and 10 is the cap (+3 standard deviations), not perfection. The vertical axis zooms to fit this company, so two charts are not comparable by eye.
Market and Valuation
Price & Market
Prev Close Price:$249.01
Open:$247.32
Day's Low:$246.25
Day's High:$253.14
Bid / Ask:-
Market Cap:36.80B
Enterprise Value:43.31B
52-Week Range
52-Week Low:$148.51
52-Week High:$258.78
Current position in 52-week range
52w Low-52w High
50-Day Avg:$227.72
200-Day Avg:$201.58
Volume
Volume Today:1,057,621
Avg Volume (3m):1,047,267
Avg Volume (10d):1,417,840
52-Week Change:+66.75%
vs S&P 500, 52 weeks:-
Beta:0.09
Valuation Multiples
P/E (trailing):107.30
Diluted EPS for the last 12 months: the four quarters ended Sep 30, 2026, from the accounts filed with the SEC on Oct 28, 2026. The P/E is the price divided by that EPS.
P/E (forward):15.31
PEG Ratio:3.39
Price / Book:1.94
Price / Sales (TTM):3.57
EV / Revenue:4.21
EV / EBITDA:13.12
Dividends
Current yield:-
Annual Dividend Rate:-
Dividend Trailing:$0.00
Yield Trailing:0.00%
5-Year Avg Yield:-
Payout Ratio:0.00%
Last Ex-Dividend Date:-
Valuation Context
P/E vs sector (indicative)
Most Recent Quarter:-
Fiscal Year (Next):-
Loading historical OHLCV database...
Date
Open
High
Low
Close
Volume
Financial Statements TTM (Trailing 12 Months)
Income Statement
Total Revenue (TTM):10.30B
Gross Profit:7.80B
EBITDA:3.30B
Net Income (TTM):347.50M
Rev Growth (YoY):+10.60%
Earnings Growth (YoY):-
Quarterly earnings growth (YoY):-
Margins
Gross Margin:-
EBITDA Margin:-
Operating Margin:-
Net Margin:-
Per Share
EPS Trailing (TTM):$2.32
Diluted EPS for the last 12 months: the four quarters ended Sep 30, 2026, from the accounts filed with the SEC on Oct 28, 2026. The P/E is the price divided by that EPS.
EPS Forward (Est.):$16.26
Revenue Per Share:$69.90
Cash Per Share:-
Book Value:$128.03
Last Dividend:-
Ex-Dividend Date:-
Last Split:-
Balance Sheet & Liquidity
Total cash:1.30B
Total Debt:7.80B
Net Debt (Debt - Cash):6.50B
Debt / Equity:41.23%
Current Ratio:1.95
Quick Ratio:0.95
Cash Flows
Operating Cash Flow:2.25B
Free Cash Flow (FCF):808.12M
FCF Yield (FCF / Market Cap):-
Enterprise Value:43.31B
EV / Revenue:4.21
EV / EBITDA:13.12
Profitability
ROE (Return on Equity):1.87%
ROA (Return on Assets):4.94%
P/E (trailing):107.30
P/E (forward):15.31
Price / Book:1.94
PEG Ratio:3.39
52-Week Change:+66.75%
S&P 500 change, 52 weeks:+11.37%
Historical Evolution (Last 4 Years)
Income Statement
Balance Sheet
Cash Flow
EPS and Earnings Per Share
Key EPS Metrics
EPS Trailing (TTM):$2.32
Diluted EPS for the last 12 months: the four quarters ended Sep 30, 2026, from the accounts filed with the SEC on Oct 28, 2026. The P/E is the price divided by that EPS.
EPS Forward (Est.):$16.26
P/E (forward):15.31
PEG Ratio:3.39
Growth and Margins
Earnings Growth YoY:-
Quarterly Earnings Growth YoY:-
Rev Growth YoY:-
Net Margin:-
Gross Margin:-
EBITDA Margin:-
Per Share
Revenue Per Share:$69.90
Cash Per Share:-
Book Value:$128.03
Cash Flows (TTM)
Free Cash Flow:808.12M
Operating Cash Flow:2.25B
EBITDA:3.30B
Total Revenue (TTM):10.30B
Net Income (TTM):347.50M
Fiscal Year (Last):-
EPS Surprise History - Last 4 Quarters
Actual vs. Analyst Estimates · Green = beat expectations · Red = missed
Quarter
Period
Actual EPS
Estimated EPS
Difference
Surprise %
Currency
Ownership Structure
Ownership Distribution
% Insiders:-
% Institutional:-
% Inst. (of Float):-
No. of Institutions:-
Visual distribution
InsidersInstitutionalFree Float
Shares & Short Interest
Shares Outstanding:147,820,223
Float (free shares):147,285,114
Short interest (shares):5,500,386
Short % of float:-
Short Ratio (days to cover):4.46
Short interest, prior month:-
Short Interest Date:-
Governance Score (1=Best, 10=Worst)
Overall risk:-
Audit Risk:-
Board risk:-
Compensation Risk:-
Shareholder rights risk:-
Top Institutional Holders
Position Change: ▲ Increased · ▼ Reduced · = Unchanged
Organization
Report Date
% Shares
No. Shares
Value (USD)
Change %
Top Mutual Funds
Position Change: ▲ Increased ▼ Decreased = Unchanged
Fund
Report Date
% Shares
No. Shares
Value (USD)
Change %
Recent Insider Trades
Executive / Insider
Title
Date
Action
Shares
Options Chain
CALLS
Strike
Last
Bid
Ask
Vol.
O.I.
IV
PUTS
Strike
Last
Bid
Ask
Vol.
O.I.
IV
Sentiment Metrics
Put/Call Ratio (Volume):-
Put/Call Ratio (O.I.):-
Max Pain (estimated):-
Total O.I. Calls:-
Total O.I. Puts:-
Expected move
Average IV (Calls ATM):-
Average IV (Puts ATM):-
Days to Expiration:-
Expected move (±):-
Biogen Inc. (BIIB) SEC filings: 10-K, 10-Q and 8-K
Direct links to financial reports filed with the SEC.
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE. It offers LEQEMBI for the treatment of Alzheimer's disease; ZURZUVAE for the treatment of postpartum depression; RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for aRelapsed or refractory diffuse large B-cell lymphoma; and other anti-CD20 therapies. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; UCB; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis; and Sage Therapeutics, Inc., as well as collaborations with Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome; Dayra Therapeutics, Inc. to develop oral macrocyclic peptides; Vanqua Bio, Inc. for developing Vanqua's preclinical oral C5aR1 antagonist compound; City Therapeutics, Inc. to develop select novel RNAi therapies; and ALTEOGEN Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Executive VP and Head of Pharmaceutical Operations & Technology
52
2.01M
Dr. Priya Singhal M.D., M.P.H.
Executive VP & Head of Development
57
2.01M
Mr. Sean Godbout
VP, Chief Accounting Officer & Global Corporate Controller
51
-
Mr. Guy Hadari
Chief Information Officer
-
-
Mr. Tim Power M.B.A., Ph.D.
Head of Investor Relations
-
-
Mr. Michael John Parini J.D.
Chief Legal Officer
51
-
You have seen the engine room
A free account saves your simulator portfolios, your personal portfolio and your Academy progress, synced across devices. And, if you switch it on, the email alert the same day an insider buys stock in their own company.
No card. No spam.
Biogen Inc. (BIIB): Quantitative Analysis
Biogen Inc. (BIIB) — Healthcare — Drug Manufacturers - General. BIIB is in the S&P 500 today. Model factor scores and market data, recalculated every trading day.
So far in 2026, BIIB has returned +41.4% against +11.4% for the S&P 500 (SPY): total return, dividends included on both sides, from Dec 31, 2025 to Nov 3, 2026.
BIIB ranks 208 of 461 on today's multifactor score, and 28 of the 55 Healthcare companies that score. Its strongest factor is momentum (Z 1.03, ranked 65 of 494); its weakest is growth (Z -0.95, ranked 474 of 489). Each factor ranks only the companies with data for it, and the multifactor score only those with all four: that is why the totals differ.
Factor scores
The Z-Score is how many standard deviations the company sits from the index average: 0 is average, positive is better than average, negative is worse.
Biogen has no announced date in the Nasdaq public calendar checked (Nov 3, 2026 to Dec 7, 2026). Of its last 12 earnings announcements: 12 before the open (SEC filings through Oct 28, 2026). BIIB earnings dates and times, quarter by quarter →
What is Biogen's P/E ratio?
Biogen's P/E (price over earnings per share for the last twelve months) is 107.3 at the Nov 3, 2026 close. That EPS is the 12-month diluted figure from the SEC, the four quarters ended Sep 30, 2026. The median of the 54 Healthcare companies with a P/E is 30.5, and the S&P 500's, 23.5: Biogen is above its sector median. Healthcare stocks, company by company →
Where does Biogen rank on Quant500?
In the Nov 3, 2026 multi-factor ranking, Biogen ranks 208 of 461, and 28 of the 55 Healthcare companies that score. The ranking orders S&P 500 companies by the average of four factors (momentum, value, quality and growth) and is recalculated every trading day. It is a model output, not investment advice. The full ranking →How it is calculated →
Have Biogen insiders bought or sold shares?
The latest open-market purchase of Biogen shares filed with the SEC (Form 4) was on Feb 12, 2026, by an officer, for $585. The latest sale was on Aug 4, 2026, by a director, for $119k. In total, from August 2025 through Nov 3, 2026: 1 purchase and 5 sales by directors, officers and large shareholders. All BIIB insider trades →
What sector is Biogen in, and which index?
Biogen is classified in the Healthcare sector (industry: Drug Manufacturers - General), per the data provider's classification (similar to GICS, not identical). It is in the S&P 500 today. It is one of the 59 S&P 500 companies in that sector. Healthcare stocks →
What is behind these numbers
The concepts on this page, explained from scratch in the Academy. Free, no account.
Quality and low volatilityWhere the quality score comes from, and why it is the factor with the most competing definitions, all of them called the same thing.
We save the portfolios you design, your own portfolio and your Academy progress, synced across devices.
Free, no card. Two automatic emails and no more: the one that confirms your address and the welcome one. After that, nothing you do not switch on yourself in your profile — such as the alert for insider buys, the same day they are reported to the SEC.